2018
DOI: 10.1056/nejmoa1706441
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Abstract: Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. (Funded by Merck; ClinicalTrials.gov number, NCT01739348 .).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

14
440
2
3

Year Published

2019
2019
2022
2022

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 548 publications
(477 citation statements)
references
References 31 publications
14
440
2
3
Order By: Relevance
“…Furthermore, the in vivo data support its efficacy for the management of AD, as the administration of a single oral dose of 10 or 30 mg/kg in rats, significantly reduced the cerebrospinal fluid (CSF) and cortical Aβ 40 . Unfortunately, all of these promising findings were overthrown by the latest results announced in May 2018, which showed the failure of verubecestat to reduce the cognitive decline in 1958 enrolled patients, along with manifested adverse events …”
Section: Bace1 As a Potential Target For The Treatment Of Alzheimer'smentioning
confidence: 99%
See 3 more Smart Citations
“…Furthermore, the in vivo data support its efficacy for the management of AD, as the administration of a single oral dose of 10 or 30 mg/kg in rats, significantly reduced the cerebrospinal fluid (CSF) and cortical Aβ 40 . Unfortunately, all of these promising findings were overthrown by the latest results announced in May 2018, which showed the failure of verubecestat to reduce the cognitive decline in 1958 enrolled patients, along with manifested adverse events …”
Section: Bace1 As a Potential Target For The Treatment Of Alzheimer'smentioning
confidence: 99%
“…Despite the success in producing potent inhibitors of BACE1 from this family, the literature lacks detailed data regarding their selectivity profile. Furthermore, it is worthy to note that the most potent BACE1 inhibitors in this class, which reached clinical trials, were recently revoked due to lack of clinical efficacy …”
Section: Bace1 As a Potential Target For The Treatment Of Alzheimer'smentioning
confidence: 99%
See 2 more Smart Citations
“…Drugs that target the production of Aß peptides, specifically the secretase inhibitor classes of drugs (ß and δ), have demonstrated a clear ability to lower Aß peptides (ie, target engagement). Yet, when introduced at the point of mild‐moderate AD, there has been no clear cognitive benefit …”
Section: Scenario 2: Aß Is a Key Trigger Of Early Disease With Diminmentioning
confidence: 99%